Why VCs fell in love with pharma R&D in 2021
pharmaphorum
APRIL 5, 2022
And investment in pharma followed suit: pharma companies were looked at as stable assets — reliable but unlikely to balloon in value like a tech company might. The risk equation changed for things like decentralised clinical trials, with companies that lacked the capacity for these trials falling behind.
52 
Let's personalize your content